Articles

Find an Article

Filter articles

Showing 221 to 230 of 737 results

Conference preview: BIO-Europe Spring

EU01-03-2018

The 12th annual BIO-Europe Spring conference, to be held in Amsterdam, the Netherlands on March 12 to 14, 2018, will allow key players in the biotech industry to come together, as Catherine Moreno Finan reports.

The licensing landscape at Pieris

US22-02-2018

Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.

A helping hand for rare diseases

US08-02-2018

Companies researching and commercialising drugs for rare diseases face unusual challenges in protecting their inventions, as Michael Yamauchi, director and patent counsel at Alexion Pharmaceuticals, tells LSIPR in an interview.

Pfizer, patents and political quagmires

30-01-2018

Politics has a huge impact on enforcement in Africa, Asia and the Middle East, a senior corporate counsel at Pfizer has told LSIPR in an interview.

From London to Amsterdam: what the EMA’s move means for medicines regulation

EU15-12-2017Rachel Bradley

While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.

LSIPR 50 2017: Leda Trivinos—Playing the long game

US10-11-2017

Thinking about how IP can assist a company long before it has fully developed is essential, says Leda Trivinos of Flagship Pioneering in an interview with LSIPR.

LSIPR 50 2017: James Topper—Venturing into biotech

US10-11-2017

Frazier Healthcare Partners has been responsible for creating and investing in multiple biotech companies, developing products from novel antibiotics to cancer therapies. James Topper, Frazier’s managing general partner, explains the firm’s philosophy.

LSIPR 50 2017: Carl Gordon—Realising great ideas

US10-11-2017

Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.

LSIPR 50 2017: Arabella Cecil—No more hand to mouth

EU10-11-2017

BACIT, a former fund of funds, has combined with life sciences investment company Syncona to form a new investment vehicle using the latter’s name. LSIPR speaks to Arabella Cecil, one of the co-founders of BACIT, about the new company’s vision.

LSIPR 50 2017: Thomas Kirkbak—Communication is key

Denmark10-11-2017

Thomas Kirkbak, chief IP litigation specialist at Danish company Lundbeck, faces challenges on several fronts, as he explains to LSIPR.

Showing 221 to 230 of 737 results

LSIPR